about
Modulation of Host miRNAs by Intracellular Bacterial PathogensVaccine development for tuberculosis: current progressEpidemiology of tuberculosis during the period 1703-2011: honoring the world tuberculosis daySpecific and randomly derived immunoactive peptide mimotopes of mycobacterial antigensScreening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.Dose of incorporated immunodominant antigen in recombinant BCG impacts modestly on Th1 immune response and protective efficiency against Mycobacterium tuberculosis in mice.Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosisMycobacterium tuberculosis pathogenesis and molecular determinants of virulenceIdentification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics.The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophagesLatent tuberculosis infection: myths, models, and molecular mechanismsIdentification of bacterial genes required for in-vivo survival.Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism.High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.The use of anti-tuberculosis therapy for latent TB infectionDevelopment of new vaccines and drugs for TB: limitations and potential strategic errorsTuberculosis vaccines: the past, present and future.How far have we reached in tuberculosis vaccine development?Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.Is the BCG vaccine safe for undernourished individuals?Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test designThe emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?BCG and BCG/DNAhsp65 vaccinations promote protective effects without deleterious consequences for experimental autoimmune encephalomyelitis.TB vaccines: current status and future perspectives.Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.Lipidated promiscuous peptide augments the expression of MHC-II molecules on dendritic cells and activates T cells.Mycobacterium-Specific γ9δ2 T Cells Mediate Both Pathogen-Inhibitory and CD40 Ligand-Dependent Antigen Presentation Effects Important for Tuberculosis Immunity.Coexpression of PPE 34.9 Antigen of Mycobacterium avium subsp. Paratuberculosis with Murine Interferon Gamma in HeLa Cell Line and Study of Their Immunogenicity in Murine Model.Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen.Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.Genetic vaccine for tuberculosis (pVAXhsp65) primes neonate mice for a strong immune response at the adult stage.A lipidated peptide of Mycobacterium tuberculosis resuscitates the protective efficacy of BCG vaccine by evoking memory T cell immunity.Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?Mycobacterium tuberculosis RpfB drives Th1-type T cell immunity via a TLR4-dependent activation of dendritic cells.Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis.
P2860
Q26740514-483CC3F8-7930-4026-915B-00C3BD3158FBQ26827737-A9781821-C81C-4F1B-A401-038D91D282F7Q27027220-82BC6D00-E977-4634-B419-621B5A04AE85Q33254366-3C075951-5D61-4E4C-8CCD-0607996B4438Q33416980-C5F6F7F0-D81D-436A-B8F2-BCA97CCE8B17Q33954601-FD211F12-8A22-4B9C-957D-6F692ACCF078Q34034191-57C4169B-466C-4C7A-8F41-DCFA35B50145Q34053027-995001E0-9F3F-4F12-B08D-2FF7F5C91B1CQ34122078-06CA4228-1162-4272-BA5D-815CC1A4D7F8Q34213787-A87E1E5E-1F4D-4B31-A1B5-BAFDF0C08BCFQ34257884-353A1C9D-D962-49F8-973D-5B674BFCCA23Q34264596-97078186-0C47-492F-AE3C-C3F76DD92CA7Q34297816-0E9ED55B-451A-4B49-B12E-7D065D097B1EQ34502595-E6198201-B930-44C0-9982-6A246C057CF9Q34581513-EA241FED-72EC-4DCE-B7F9-61174D090370Q34681015-3BBBC3EC-F116-47C9-9CE1-CDD21859DDABQ35026573-00BBED01-469C-4D6F-9B92-A7E63AC34ADCQ35065531-ED54A647-C026-4A41-8163-C44BB6C887A7Q35193467-3319DC56-4474-4BC0-B42D-CA2159DF0639Q35592360-D52856BC-CA2C-4CFF-9904-70DF47DBB9EBQ35748061-27542A42-A346-4E3E-86F6-D9AA2B95E805Q35903952-06C642D2-6FBC-48A9-A12A-FE2B60253F8BQ36227440-5DA69991-4A50-4C4F-89AE-327CE7607A26Q36565187-92A62A6C-6579-44ED-959A-A82A610B1F45Q37316205-7FFCFD08-EB2B-4D2A-9D12-694E8A5DC1FDQ37435926-0F9D68B5-B413-4A28-BD61-4AC7C68C37A0Q37523075-6093FF8E-EC99-4AE6-A160-FC235EED8855Q37592378-C71FE526-F496-4523-B99B-89E2805A8D44Q38813812-AC31337D-838A-43EB-801B-BE99565E7F3CQ39586299-72571C5B-77A3-49C4-9168-D604B9CF2587Q39671749-76CA3563-79FE-4531-9C18-BEF32EE2FE03Q39961868-9FD1DE20-DCE0-4986-95B0-8DF037815F94Q39982362-30D87C28-E2FA-434C-859B-A25D0FA050BFQ41909672-A56B7023-8DE1-490C-BA1C-3A971F01AA81Q41922740-E992E645-D2F7-4DA8-9FC6-BE5D8A9F12DCQ42210000-17DCA3E5-B4FC-4B13-980F-E933FD7623D7Q42413220-297297EA-DE99-41B7-8CC7-99971BCBF104Q42692800-41689CB5-D17C-47DD-8E1E-2D1F16E8BA77Q44400658-D77668F9-0291-4F9F-AA34-B1FD3BAC1664Q44542547-18BB0C68-95BA-4C13-9F02-D13C3F102908
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
TB vaccines: progress and problems.
@ast
TB vaccines: progress and problems.
@en
TB vaccines: progress and problems.
@nl
type
label
TB vaccines: progress and problems.
@ast
TB vaccines: progress and problems.
@en
TB vaccines: progress and problems.
@nl
prefLabel
TB vaccines: progress and problems.
@ast
TB vaccines: progress and problems.
@en
TB vaccines: progress and problems.
@nl
P1433
P1476
TB vaccines: progress and problems
@en
P2093
Andersen P
P304
P356
10.1016/S1471-4906(01)01865-8
P577
2001-03-01T00:00:00Z